Underlining the current vogue for antibody-based technologies, Alcon Inc. is acquiring the ophthalmology business of ESBATech AG for $150 million in cash plus up to $439 million in potential milestones. (BioWorld International)

LONDON - Summit Corp. plc completed the life-saving divestment of its services businesses, selling its Dextra Laboratories subsidiary to New Zealand Pharmaceuticals for £950,000 (US$1.6 million). (BioWorld International)